CA
NZ
UK
AU
IND
US
National Vision Holdings, Inc. (NASDAQ: EYE) reported net revenue of $498.8 million for the quarter ended July 4, 2026, a 2.5% increase from the prior year. The strong performance was fueled by new store openings and solidDemandsignals, with comparable store sales growth reported at …
LENZ Therapeutics, Inc. reported $5.5 million in Q2 revenue, surpassing the consensus estimate of $-1.10 per share, with strong patient persistence and global license agreements. ThisRevenuegrowth matters to investors as it indicates a positive trend for the company's commercialization strategy.Key HighlightsLENZ has expanded its …
Liquidia Corp (NASDAQ: LQDA) reported second-quarter product sales of approximately $170.4 million, reflecting a 31% increase from the prior quarter. Liquidia'sNet Incomefor the quarter reached $74.7 million, underscoring its increasing profitability and ability to generate positiveCash Flowamidst a competitive environment. The company’s EPS of …
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) announced a net loss of $28.6 million for the second quarter ending June 30, resulting in an EPS of $-0.21, which slightly missed the consensus estimate of $-0.20. This marks a significant escalation from a loss of $13 million …
Immunome Inc. (NASDAQ: IMNM) reportedEarningsthat topped expectations, posting EPS of $‑0.48 versus a $‑0.57 consensus, and unveiled Phase 3 RINGSIDE data that cut disease‑progression risk by 84% compared with placebo.
The adjusted earnings per share also beat expectations, reaching $2.90 against a forecast of $2.85. This strong performance signals ongoing strength inDemandacross various sectors, enhancing investor confidence.
Kyverna Therapeutics (NASDAQ: KYTX) announced a cash balance of $199.4 million as of the quarter ended June 30, 2026, a level that extends its operating runway through 2028. The company reportedEarnings Per Sharethat outperformed analyst expectations, underscoring disciplined cost management despite a challenging market …
ENvue Medical, Inc. (NASDAQ: FEED) has established a committed equity facility totaling $50 million, allowing the company to sell its shares of common stock. The financing arrangement, entered into with an institutional investor on August 12, 2026, will enable ENvue to utilize market conditions …
Erasca, Inc. (NASDAQ: ERAS) reported a net loss of $44.1 million for the second quarter ending June 30, 2026, as it continues to invest heavily in its clinical programs. The company is focused on advancing its pipeline, particularly the promising ERAS-0015 trials targeting KRAS-driven …
Century Therapeutics, Inc. (NASDAQ: IPSC) posted a net loss of $34.6 million for the second quarter of 2026, compared to a higher loss of $32.5 million in the prior year’s quarter. This outcome reflects ongoing investments inResearch and Developmentinitiatives, particularly in advancing its innovative …
Please wait processing your request...